Read Official PR here

15th April 2012:SG Austria acquires world-wide rights for in vivo production method for antibodies- Press Release in Biospectrum Asia, April 2012

Singapore based biotech company SG Austria, the leading living cell encapsulation company, has acquired all rights to a patent family claiming the secretion of antibodies and antibody-like molecules from encapsulated cells. The technology allows continuous, steady state, secretion of therapeutic antibodies from the implanted cells, thereby avoiding the typical peaks and troughs associated with more conventional antibody delivery systems and immunization schemes. The inventors demonstrated safe, long term antibody production after a single implantation of the beads in mouse models as well as the use of the technology in a therapeutic setting to protect against a lethal virus disease. In principle, the technology can be used to treat any virus induced disease for which neutralizing antibodies can be generated such as hepatitis B, hepatitis C, human immunodeficiency virus (HIV), West Nile virus, the SARS causing coronavirus and new variants of influenza virus. In addition, the technology can be used to improve current monoclonal antibody therapies for cancer treatment such as Herceptin, Rituxan, Avastin, Erbitux and Mylotarg


Micro-encapsulation of living cells for immuno-protection and localization in patients

Cell Encapsulation